Core Insights - Compass Therapeutics, Inc. has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, effective January 1, 2026, to enhance its leadership team in oncology-focused biopharmaceutical development [1][2] Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for multiple human diseases, particularly in oncology [4] - The company aims to target critical biological pathways necessary for effective anti-tumor responses, including angiogenesis modulation and immune response activation [4] Leadership Experience - Arjun Prasad brings extensive experience in oncology product launches, having successfully led over 10 launches, including the notable VORANIGO® in 2024 and TIBSOVO® for biliary tract cancer [2][3] - Cynthia Sirard has over two decades of experience in oncology drug development, with a focus on gastrointestinal cancers and has led multiple programs through regulatory approval processes [3] Strategic Goals - The appointments of Prasad and Sirard are expected to significantly enhance Compass's ability to deliver innovative therapies, particularly for biliary tract cancer and other oncology indications [2][3] - The company is approaching transformational milestones for its lead candidate, tovecimig, and aims to advance its robust pipeline of therapies [4]

Summary of Key Points from Biotechnology Equity Research Conference Call Industry Overview - The report focuses on the biotechnology sector, specifically highlighting companies with significant potential for growth and upcoming catalysts in 2026. Key Companies and Their Outlook 1. **Dianthus Therapeutics, Inc. (DNTH)** - Market Cap: $1.82 billion - Price Target: $66 - Key catalysts include: - CIDP Phase III interim analysis in Q2 2026 - Initiation of gMG Phase III study in mid-2026 - Phase II MMN topline data in 2H26 - Potential for significant upside based on peak revenue estimates of ~$2 billion across neuromuscular diseases [19][20][24] 2. **Taysha Gene Therapies, Inc. (TSHA)** - Market Cap: $1.50 billion - Price Target: $11 - Focus on pivotal study for TSHA-102 in Rett syndrome with potential for a 6-month interim readout by YE26/1Q27 [26][27] 3. **Tyra Biosciences (TYRA)** - Market Cap: $1.36 billion - Price Target: $32 - Major catalysts include: - Phase III data for achondroplasia in early 2026 - Initial data for IR-NMIBC in 1H26 - Potential to disrupt the market with oral FGFR3 inhibitors [31][35] 4. **Tango Therapeutics, Inc. (TNGX)** - Market Cap: $1.15 billion - Price Target: $14 - Expected to show de-risking data for vopimetostat in combination with RVMD's RAS inhibitors in 2026 [37][40] 5. **ORIC Pharmaceuticals (ORIC)** - Market Cap: $783 million - Price Target: $23 - Key catalysts include dose-optimization data for prostate cancer and validating data from PFE's MEVPRO-1 trial [42][48] 6. **Solid Biosciences (SLDB)** - Market Cap: $463 million - Price Target: $15 - Focus on DMD program with key regulatory feedback expected in 1H26 [49][53] Major Catalysts and Events - **Upcoming Catalysts:** - RARE and MREO Phase III ORBIT final analysis expected in Dec'25/Jan'26 with potential stock movements of +100%/-30% [2] - ALNY, CRSP, and others expected to provide revenue guidance and business plans early in 2026 [1] - Regulatory events including FDA's Rare Disease Day on 2/23/26 [12] - **Drug Launches:** - Expected launches in 2026 include drugs from ALNY, ARWR, KALV, and others targeting various conditions [3] Financial Updates - **Price Target Changes:** - ARWR raised from $67 to $90 - KOD raised from $24 to $39 [6][10] Market Dynamics - **Pricing Stability:** - 2026 net pricing expected to remain stable with current Medicare contracts influencing high gross-to-net (GTN) guidance [12] - **Strategic Interest:** - Potential for M&A activity as companies like ORIC attract interest due to their prostate cancer programs [43] Conclusion - The biotechnology sector is poised for significant developments in 2026, with multiple companies presenting strong investment opportunities based on upcoming catalysts, drug launches, and strategic positioning in the market.

Core Insights - Jefferies has released a report on the outlook for the U.S. biotech industry in 2026, highlighting key clinical trial data disclosures, new drug approvals, and policy dynamics that could lead to value re-evaluation for companies in the sector [1] Six Preferred Stocks - Jefferies identified six companies as core recommendations for 2026 based on market catalysts and valuation potential: - Dianthus Therapeutics (DNTH.US), target price $66: Focused on claseprubart for various neuromuscular diseases, with peak revenue estimated at $2 billion [2] - Taysha Gene Therapies (TSHA.US), target price $11: TSHA-102 for Rett syndrome, with peak revenue potential of $2 billion and a key trial data disclosure expected by the end of 2026 [2] - Tyra Biosciences (TYRA.US), target price $32: Dabogratinib for bladder cancer and achondroplasia, with critical data expected next year [3] - Tango Therapeutics (TNGX.US), target price $14: Collaboration with Revolution Medicines for a pancreatic cancer treatment, with data expected in mid-2026 [3] - ORIC Pharmaceuticals (ORIC.US), target price $23: Two potential assets targeting prostate cancer and lung cancer, with key data expected next year [4] - Solid Biosciences (SLDB.US), target price $15: Focused on gene therapy for Duchenne muscular dystrophy, with critical meetings with the FDA planned for 2026 [4] Seven Undervalued Companies - The report also highlighted seven undervalued companies with significant catalysts: - Ultragenyx Pharmaceutical (RARE.US), target price $114: Expected key catalysts in 2026, including data for treatments for osteogenesis imperfecta and Angelman syndrome [5] - Beam Therapeutics (BEAM.US), target price $41: Updates on AATD therapy and SCD therapy expected in 2026, showcasing strong potential [5] - Aurinia Pharmaceuticals (AUPH.US), target price $21: Steady growth in lupus nephritis treatment, with new drug development paths expected to expand growth [6] - Kodiak Sciences (KOD.US), target price $39: Anticipated data from three pivotal trials in 2026, with significant potential for stock volatility [7] - Intellia Therapeutics (NTLA.US), target price $45: Key data for hereditary angioedema therapy expected in mid-2026, with sufficient cash reserves to support operations [7] - Compass Therapeutics (CMPX.US), target price $8: Data for cholangiocarcinoma therapy expected in early 2026, with a significant market opportunity [8] - KalVista Pharmaceuticals (KALV.US), target price $38: First oral treatment for hereditary angioedema expected to see rapid growth in 2026 [8] Five Potential Acquisition Targets - Jefferies identified five companies that may become acquisition targets in 2026 due to their unique assets or market positions: - Arrowhead Pharmaceuticals (ARWR.US): Strong RNAi product line for cardiovascular and metabolic diseases [9] - Celcuity (CELC.US): Unique efficacy of gedatolisib in breast cancer [9] - ORIC Pharmaceuticals: High-value prostate and lung cancer projects [9] - Travere Therapeutics (TVTX.US): Potential for significant market expansion in rare kidney diseases [9] - KalVista Pharmaceuticals: First-mover advantage in oral HAE treatment [9]

Core Insights - Compass Therapeutics, Inc. (NASDAQ:CMPX) is recognized as one of the top multibagger stocks to consider for investment leading into 2026 [1] Analyst Coverage - Canaccord analyst John Newman initiated coverage of CMPX with a "Buy" rating and a $10 price target, citing positive data from second-line biliary tract cancer studies as a key factor [2] - Citizens JMP analyst Reni Benjamin also initiated coverage with an "Outperform" rating and a $10 price target, highlighting a 17% overall response rate for tovecimig in combination with paclitaxel in biliary tract cancers, compared to 5% in the paclitaxel-only arm [3] Clinical Progress - In the Q3 2025 update, management indicated that analyses of key secondary endpoints from the COMPANION-002 Phase 2/3 trial are expected to be reported in late Q1 2026 [4] - Preparations are underway for a Phase 2 basket study targeting multiple DLL4-positive tumors, alongside ongoing enrollment in a first-line combination trial [4] Company Overview - Compass Therapeutics is a clinical-stage oncology biopharmaceutical company focused on developing proprietary antibody-based therapies aimed at treating various cancers through mechanisms such as targeting angiogenesis and immune activation [5]

Group 1 - Compass Therapeutics, Inc. (CMPX) is a notable stock in the Medical sector, showing strong year-to-date performance compared to its peers [1][4] - The Medical sector consists of 946 individual stocks, with Compass Therapeutics ranked within the top 4 in the Zacks Sector Rank [2] - The Zacks Rank system indicates that Compass Therapeutics has a Zacks Rank of 2 (Buy), suggesting a favorable outlook for the stock [3] Group 2 - The Zacks Consensus Estimate for CMPX's full-year earnings has increased by 19.7% in the past quarter, indicating improved analyst sentiment [4] - CMPX has achieved a year-to-date return of approximately 247.6%, significantly outperforming the average return of 6% for Medical companies [4] - Compass Therapeutics is part of the Medical - Biomedical and Genetics industry, which includes 464 companies and has an average gain of 17.7% this year, further highlighting CMPX's strong performance [6] Group 3 - Another stock in the Medical sector, Arcutis Biotherapeutics, Inc. (ARQT), has also shown strong performance with a year-to-date return of 99.4% and a Zacks Rank of 2 (Buy) [5] - The consensus EPS estimate for Arcutis Biotherapeutics has increased by 46.5% over the past three months, reflecting positive analyst sentiment [5] - Investors are encouraged to monitor both Compass Therapeutics and Arcutis Biotherapeutics for their continued strong performance in the Medical sector [7]

Core Viewpoint - Compass Therapeutics, Inc. is set to present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026, highlighting its focus on developing proprietary antibody-based therapeutics for oncology [1]. Presentation Details - The presentation will take place on January 14, 2026, at 7:30 AM PT, and will be available via webcast [2]. - The presentation will be archived on Compass' Events page for future access [2]. - Investors can schedule one-on-one meetings with Compass on the same day by contacting their J.P. Morgan representative [2]. Investor Meetings - Compass will also host investor meetings during the LifeSci Partners Corporate Access Event on January 12 and 13, 2026, in San Francisco, CA [3]. - Interested investors should reach out to their LifeSci representative to arrange a meeting [3]. Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics to address multiple human diseases [4]. - The company emphasizes the interplay between angiogenesis, the immune system, and tumor growth, aiming to create a robust pipeline of novel product candidates [4]. - Its product candidates target critical biological pathways necessary for effective anti-tumor responses, including angiogenesis modulation and immune response activation [4]. - Founded in 2014, Compass Therapeutics is headquartered in Boston, Massachusetts [4].

Core Viewpoint - Compass Therapeutics, Inc. (CMPX) has shown a 13% gain over the past four weeks, with a mean price target of $12.62 indicating a potential upside of 134.1% from the current price of $5.39 [1] Price Targets and Analyst Estimates - The mean estimate consists of 13 short-term price targets with a standard deviation of $6.67, where the lowest estimate is $8.00 (48.4% increase) and the highest is $30.00 (456.6% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about CMPX's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 1.6% over the past month, indicating a positive outlook [12] - CMPX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' price targets can often be overly optimistic due to business incentives [3][8] - While price targets should not be ignored, they should be approached with skepticism, as they may not accurately predict stock price movements [10]

Core Insights - Compass is a monoclonal antibody discovery and development company focused on oncology, based in Boston [1] - The company currently has three drugs in clinical trials and a fourth drug set to enter the clinic [1] - 2026 is anticipated to be a significant year for the company with important updates expected [1] Drug Development Updates - The lead program, Tovecimig, is a DLL4xVEGF-A bispecific antibody, with readouts on secondary endpoints of progression-free survival and overall survival expected by the end of Q1 2026 [1] - In the second half of 2025, the company observed significant efficacy in a Phase I clinical trial of a PD-1, PD-L1 bispecific antibody, with three responses noted in the first 15 patients treated [2] - The company plans to expand cohorts for patients with triple-negative breast cancer and non-small cell lung cancer based on the observed efficacy [2]

Core Insights - The company has seen a significant stock price increase of 290% year-to-date, outperforming the XBI index which is up 30% [1] - The company is focused on monoclonal antibody discovery and development in oncology, with three drugs currently in clinical trials [2] Clinical Programs Overview - The most advanced program is a DLL4 VEGF-A bispecific antibody named tovecimig, which is in a randomized trial for patients with advanced biliary tract cancer [3] - The company reported achieving the primary endpoint in a randomized trial, with the overall response rate more than tripling compared to the control arm [3]

Summary of Compass Therapeutics FY Conference Call Company Overview - **Company**: Compass Therapeutics - **Industry**: Biotechnology, specifically focused on monoclonal antibody discovery and development in oncology - **Location**: Boston - **Current Pipeline**: Three drugs in clinical trials, with a fourth drug about to enter the clinic [2][3] Key Points and Arguments Upcoming Milestones - **Tevesemig**: A DLL4 VEGF-A bispecific antibody with a readout on secondary endpoints of progression-free survival (PFS) and overall survival (OS) expected by the end of Q1 2026 [2][3] - **PD-1, PD-L1 Bispecific Antibody**: Observed three responses in the first 15 patients treated in a phase 1 clinical trial, with cohort expansions planned for triple-negative breast cancer and non-small cell lung cancer [2][3][31] - **Fourth Drug**: A novel PD-1 VEGF-A bispecific antibody entering the clinic at the beginning of 2026 [3][4] Clinical Trial Insights - **Tevesemig Efficacy**: In a randomized study, the response rate in the combination arm (including Tevesemig) was more than triple that of the control arm, with a significant reduction in progressive disease incidence (42% in control vs. 16% in combination arm) [5][6][9] - **Survival Data**: Observations indicate fewer deaths than projected, suggesting improved overall survival [7][9][10] Market Opportunity - **Biliary Tract Cancer (BTC)**: Approximately 25,000 patients diagnosed annually in the U.S., with an estimated 15,000 patients eligible for second-line therapy, representing a multi-billion-dollar commercial opportunity [11][14] - **Duration of Therapy**: Current second-line chemotherapy duration is low single-digit months, while Tevesemig showed a median PFS of 9.4 months in a phase 2 study [12][14] Expansion Plans - **Frontline Studies**: Ongoing studies at MD Anderson to evaluate Tevesemig in combination with existing regimens, potentially increasing patient numbers by 50% [15][17] - **Additional Indications**: DLL4 expression is enriched in various malignancies, including hepatocellular, gastric, ovarian, renal cell, and colorectal cancers, indicating further expansion potential [17][18] Commercial Readiness - **Manufacturing Capability**: Compass has developed a robust commercial-ready manufacturing process for Tevesemig [20][21] - **Prescriber Awareness**: Initial pre-commercial work has begun, with plans for a full commercial launch preparation for a potential 2027 launch [20][21] Unique Mechanisms - **PD-1, PD-L1 Bispecific Antibody (8371)**: Utilizes a novel technology called StitchMabs, allowing for unique mechanisms of action, including T cell engagement and PD-1 cleavage [22][25] - **Differentiation**: The drug is positioned to have better PD-1 blockade compared to other molecules in development, with a focus on its unique mechanism [33][34] Other Important Insights - **Clinical Observations**: Notable responses in patients previously treated with other therapies, indicating potential for significant clinical impact [31] - **Future Indications**: Plans to explore additional indications for the PD-1 VEGF bispecific, including gastric cancer, hepatocellular, renal cell, and endometrial cancer [34] This summary encapsulates the critical insights and future directions for Compass Therapeutics as discussed in the conference call.